Dr. Craig Tendler brings over 25 years of experience in oncology research and development, with a distinguished track record of guiding transformative therapies from early-stage clinical development through global regulatory approvals. He most recently served as Vice President of Oncology Clinical Development, Diagnostics, and Global Medical Affairs at Johnson & Johnson Innovative Medicine, where he was instrumental in the development and approval of numerous groundbreaking cancer therapies.

During his tenure at Johnson & Johnson, Craig led the development and global approval of ZYTIGA®, ERLEADA®, DARZALEX®, CARVYKTI®, IMBRUVICA®, and RYBREVANT®. Under his leadership, the company achieved over 30 major drug approvals, including 15 New Drug Applications, and was instrumental in securing 13 Breakthrough Therapy Designations from the U.S. FDA across both solid tumors and hematologic malignancies.

Prior to joining Johnson& Johnson, Craig served as Vice President of Oncology Clinical Research at Schering-Plough, where he also chaired the company’s Oncology Licensing Committee. He has also held faculty appointments at the Mount Sinai School of Medicine and conducted research as a physician-scientist fellow at the National Cancer Institute.

Craig earned his M.D. with honors from the Icahn School of Medicine at Mount Sinai and his undergraduate degree from Cornell University.

‍